Yttrium chloride (Yttriga)
Ability to drive, yttrium chloride [2] ---> SmPC of [2] of EMA
Effects on ability to drive and to use machines following treatment by Yttrium (90Y)-labelled medicinal products will be specified in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Breast-feeding, yttrium chloride [2] ---> SmPC of [2] of EMA
If the administration cannot be delayed, a lactating mother should be advised to stop breast-feeding.
Fertility, yttrium chloride [2] ---> SmPC of [2] of EMA
Further information concerning the use of a Yttrium (90Y)-labelled medicinal concerning fertility is specified in the Summary of Product Characteristics of the medicinal product to be radiolabelled.
Pregnancy, yttrium chloride [2] ---> SmPC of [2] of EMA
Yttrium (90Y)-labelled medicinal products are contraindicated in established or suspected pregnancy or when pregnancy has not been excluded
Women of childbearing potential, yttrium chloride [2] ---> SmPC of [2] of EMA
Women of childbearing potential have to use effective contraception during and after treatment.
CONTRAINDICATIONS of Yttrium chloride (Yttriga)
Do not administer Yttriga directly to the patient.
Yttriga is contraindicated in the following cases:
- Hypersensitivity to Yttrium (90Y) chloride or to any of the excipients
Yttrium (90Y)-labelled medicinal products are contraindicated in the following case:
- Established or suspected pregnancy or when pregnancy has not been excluded
For information on contraindications to particular Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga refer the Summary of Product
Characteristics / package leaflet of the particular medicinal product to be radiolabelled.
https://www.ema.europa.eu/en/documents/product-information/yttriga-epar-product-information_en.pdf 29/01/2021
Other trade names: Ytracis, Theryttrex,